Heart Disease & Cardiology Clinical Trials Update: Week 26, 2026

Published June 26, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

This large Phase 3 study tested the cholesterol-lowering drug evolocumab in adults at high risk for heart disease who have never had a heart attack or stroke. With over 12,000 participants worldwide, the trial explored whether evolocumab could help reduce future major heart problems in this group. The results, now available, may offer a new option for people looking to lower their risk before serious events occur.

A Study of Cardiovascular Events iN Diabetes Plus

This Phase 4 trial is investigating the oral medication semaglutide for adults with type 2 diabetes to see if it can reduce heart attacks and strokes. Conducted in the United Kingdom, the study focuses on patients without previous heart attacks or strokes. If successful, semaglutide could become a valuable tool for lowering cardiovascular risks in people managing diabetes.

ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

This ongoing Phase 4 trial in South Korea is examining whether combining aspirin with high-intensity statin treatment can better prevent heart problems in individuals who have severe calcium buildup in their coronary arteries. By studying 5,000 participants, the trial aims to improve prevention strategies for those at high risk of heart disease. The findings could help guide future recommendations for treatment.

AI-ECG for One-Year Mortality Risk Prediction

This completed study tested an artificial intelligence tool that analyzes ECGs to predict the risk of dying within one year from heart-related causes. Using data from over 460,000 patients in Taiwan, the software could help doctors identify which patients with suspected heart disease need closer monitoring or more aggressive treatment. Such technology may improve how risks are assessed using a simple and common heart test.

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

This trial is recruiting 7,000 participants across China to evaluate whether adding Repatha, a cholesterol-lowering medication, to standard care can better prevent major heart and vascular events in people with established atherosclerotic cardiovascular disease. The study’s results could provide important insights for managing heart disease in the Chinese population and potentially improve outcomes.

This week saw promising progress in heart disease research, with studies exploring new medications, prevention strategies, and innovative technologies to better assess and reduce cardiovascular risks. These trials highlight ongoing efforts to offer more personalized and effective care for patients worldwide.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.